McIlrath & Eck’s Quest Diagnostics DGX Stock Holding History

McIlrath & Eck’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36K	Buy	184 +1	+0.5%	+$194	﹤0.01%	647
2025 Q4	$31.8K	Buy	+183	New	+$33.3K	﹤0.01%	431

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

McIlrath & Eck's DGX Position: Q1 2026 in Review

McIlrath & Eck increased its Quest Diagnostics (DGX) stake by 0.55% in Q1 2026, buying an estimated $194 and bringing the position to 184 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #647.

McIlrath & Eck first reported a position in DGX in Q4 2025 and has held it in 2 quarters since. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

McIlrath & Eck held 184 shares of Quest Diagnostics worth $36K as of Q1 2026.
McIlrath & Eck bought 1 Quest Diagnostics share in Q1 2026, an estimated $194.
Quest Diagnostics made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #647 holding.
McIlrath & Eck first reported a position in Quest Diagnostics in Q4 2025 and has held it in 2 quarters since.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.